Phosphodiesterase 5 Inhibitor Sildenafil Inhibits HPV+ Cervical Cancer Cells and Cervical Cancer Stem Cells by Apoptotic Induction and Telomerase Activity Modulation
Abstract
Background/aim: Cervical cancer mortality has since long been associated with HPV positivity. However, emerging evidence points to the significant role of cancer stem cells (CSCs) in tumorigenesis, metastasis, relapse, and chemoresistance. This necessitates targeting strategies not only against HPV+ cervical cancer cells but also against CSCs. Selective phosphodiesterase type 5 inhibitors are well-known as examples of successful drug repurposing. In a small screen, previous research identified cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE) inhibition as a potential strategy for targeting cancer stem cell maintenance and survival in various cell lines. Hence, herein we studied the status of cGMP-PDE and its modulation in cervical cancer.
Materials and methods: The expression of phosphodiesterase isoforms in HPV+ (HeLa and SiHa) and HPV- (C33A) cervical cancer cell lines was studied to identify cancer-enhanced PDE isoforms. The efficacy of the corresponding PDE isoform inhibitor sildenafil was evaluated through an MTT assay and functional assays, including colony formation, cell migration, cell cycle analysis, apoptosis, DNA laddering, and telomerase activity assessment. Additionally, cAMP and cGMP levels were analyzed upon sildenafil treatment, and cervical cancer spheroids were examined using a live-dead cell assay.
Results: cGMP-dependent PDE5 was identified as a cervical cancer-enhanced isoform that is modulated effectively by sildenafil. Sildenafil increased…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.